Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia

In the last few years, new drugs able to inhibit the B-cell receptor (BCR) pathway have been approved by the US and European drug control agencies for the treatment of chronic lymphocytic leukemia (CLL) and some indolent B lymphomas. Among them, ibrutinib and idelalisib, respectively, target the

[1]  F. Bosch,et al.  Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. , 2018, Future oncology.

[2]  D. Kontoyiannis,et al.  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  A. Kater,et al.  Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach , 2017, Haematologica.

[4]  S. Choi,et al.  Assessment of cytomegalovirus and cell-mediated immunity for predicting outcomes in non-HIV-infected patients with Pneumocystis jirovecii pneumonia , 2017, Medicine.

[5]  C. Grommes,et al.  Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. , 2017, Cancer cell.

[6]  M. Keating,et al.  Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. , 2015, Clinical lymphoma, myeloma & leukemia.

[7]  N. Chiorazzi,et al.  B cell receptor signaling in chronic lymphocytic leukemia. , 2013, Trends in immunology.

[8]  Jeffrey A Jones,et al.  Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals , 2010 .

[9]  Dalya R. Soond,et al.  PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. , 2010, Blood.

[10]  A. Baron,et al.  Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  K. Okkenhaug,et al.  Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K , 2007, Trends in immunology.

[12]  K. Okkenhaug,et al.  The p110δ Isoform of Phosphoinositide 3-Kinase Controls Clonal Expansion and Differentiation of Th Cells1 , 2006, The Journal of Immunology.